Sacituzumab tirumotecan plus bevacizumab for platinum-resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) for women whose ovarian cancer stopped responding to platinum chemotherapy. The goal is to see if the combination helps shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have ovarian, primary peritoneal, or fallopian tube cancer that returned within 6 months of your last platinum chemo.
- You must have had 1 to 3 prior cancer treatments (could include bevacizumab or a PARP inhibitor).
- You must be in fairly good overall health (able to take care of yourself, no major organ problems).
- You must not be pregnant and agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a combination of two drugs (sacituzumab govitecan and bevacizumab) to standard chemotherapy for ovarian cancer that has come back after treatment with a PARP inhibitor. It is for people whose cancer has a BRCA mutation or is homologous recombination deficient.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer (PROC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.